Products billed under this code include Rebinyn, Recombi.
The billing unit for this code changed over time, so payment limits from different quarters may not be directly comparable. Check the billing unit column below.
Payment limit per 1 IU, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Rebinyn | Novo Nordisk, Inc | 00169-7901-01 | 1 | $4.715 |
| Rebinyn | Novo Nordisk, Inc | 00169-7902-01 | 1 | $4.715 |
| Rebinyn | Novo Nordisk, Inc | 00169-7905-01 | 1 | $4.715 |
| Recombi | Novo Nordisk, Inc | 00169-7903-01 | 1 | $4.715 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $4.715 | +$0.041 | 1 IU | Factor ix recomb gly rebinyn | v1, posted September 17, 2026 |
| 3Q26 | $4.674 | +$0.178 | 1 IU | Factor ix recomb gly rebinyn | v1, posted September 15, 2026 |
| 2Q26 | $4.496 | −$0.054 | 1 IU | Factor ix recomb gly rebinyn | v1, posted September 15, 2026 |
| 1Q26 | $4.55 | +$0.088 | 1 IU | Factor ix recomb gly rebinyn | v1, posted September 15, 2026 |
| 4Q25 | $4.462 | −$0.117 | 1 IU | Factor ix recomb gly rebinyn | v1, posted September 8, 2026 |
| 3Q25 | $4.579 | +$0.259 | 1 IU | Factor ix recomb gly rebinyn | v1, posted March 10, 2026 |
| 2Q25 | $4.32 | −$0.074 | 1 IU | Factor ix recomb gly rebinyn | v1, posted March 10, 2026 |
| 1Q25 | $4.394 | −$0.171 | 1 IU | Factor ix recomb gly rebinyn | v1, posted December 19, 2025 |
| 4Q24 | $4.565 | +$0.059 | 1 IU | Factor ix recomb gly rebinyn | v1, posted June 11, 2025 |
| 3Q24 | $4.506 | +$0.032 | 1 IU | Factor ix recomb gly rebinyn | v1, posted June 11, 2025 |
| 2Q24 | $4.474 | +$0.065 | 1 IU | Factor ix recomb gly rebinyn | v1, posted March 11, 2025 |
| 1Q24 | $4.409 | +$0.005 | 1 IU | Factor ix recomb gly rebinyn | v1, posted December 19, 2024 |
| 4Q23 | $4.404 | −$0.01 | 1 IU | Factor ix recomb gly rebinyn | v1, posted October 10, 2024 |
| 3Q23 | $4.414 | – | 1 IU | Factor ix recomb gly rebinyn | v1, posted June 5, 2024 |
| 2Q23 | $4.328 | +$0.19 | 1 MG | Factor ix recomb gly rebinyn | v1, posted February 23, 2024 |
| 1Q23 | $4.138 | −$0.021 | 1 MG | Factor ix recomb gly rebinyn | v1, posted December 6, 2023 |
| 4Q22 | $4.159 | −$0.044 | 1 MG | Factor ix recomb gly rebinyn | v1, posted June 22, 2023 |
| 3Q22 | $4.203 | +$0.132 | 1 MG | Factor ix recomb gly rebinyn | v1, posted June 9, 2023 |
| 2Q22 | $4.071 | −$0.198 | 1 MG | Factor ix recomb gly rebinyn | v1, posted December 14, 2022 |
| 1Q22 | $4.269 | +$0.043 | 1 MG | Factor ix recomb gly rebinyn | v1, posted June 8, 2022 |
| 4Q21 | $4.226 | +$0.14 | 1 MG | Factor ix recomb gly rebinyn | v1, posted June 2, 2022 |
| 3Q21 | $4.086 | +$0.126 | 1 MG | Factor ix recomb gly rebinyn | v1, posted June 2, 2022 |
| 2Q21 | $3.96 | +$0.001 | 1 MG | Factor ix recomb gly rebinyn | v1, posted March 1, 2022 |
| 1Q21 | $3.959 | – | 1 MG | Factor ix recomb gly rebinyn | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
